Exact Mass: 421.3165074
Exact Mass Matches: 421.3165074
Found 168 metabolites which its exact mass value is equals to given mass value 421.3165074,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Talatizamine
Talatizamine is a diterpenoid. Origin: Plant; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid Talatisamine, a aconitum alkaloid, is specific K+ channel blocker. Talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons[1]. Talatisamine, a aconitum alkaloid, is specific K+ channel blocker. Talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons[1].
Gamma-linolenyl carnitine
C25H43NO4 (421.31919180000006)
gamma-Linolenyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] gamma-linolenyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).
Alpha-linolenyl carnitine
C25H43NO4 (421.31919180000006)
alpha-linolenyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] alpha-linolenyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).
(9Z,11E,13Z)-Octadeca-9,11,13-trienoylcarnitine
C25H43NO4 (421.31919180000006)
(9Z,11E,13Z)-Octadeca-9,11,13-trienoylcarnitine is an acylcarnitine. More specifically, it is an (9Z,11E,13Z)-octadeca-9,11,13-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z,11E,13Z)-Octadeca-9,11,13-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z,11E,13Z)-Octadeca-9,11,13-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,9Z,12Z)-Octadeca-5,9,12-trienoylcarnitine
C25H43NO4 (421.31919180000006)
(5Z,9Z,12Z)-Octadeca-5,9,12-trienoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,9Z,12Z)-octadeca-5,9,12-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,9Z,12Z)-Octadeca-5,9,12-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z,9Z,12Z)-Octadeca-5,9,12-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(8E,10E,12Z)-Octadeca-8,10,12-trienoylcarnitine
C25H43NO4 (421.31919180000006)
(8E,10E,12Z)-octadeca-8,10,12-trienoylcarnitine is an acylcarnitine. More specifically, it is an (8E,10E,12Z)-octadeca-8,10,12-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8E,10E,12Z)-octadeca-8,10,12-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8E,10E,12Z)-octadeca-8,10,12-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Stearoyl Histidine
C24H43N3O3 (421.33042480000006)
N-stearoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Nevanimibe
C471 - Enzyme Inhibitor
N6-[2-[5-(Diethylamino)pentan-2-ylamino]-6-methyl-4-pyrimidinyl]-2-methylquinoline-4,6-diamine
NSC 23766 is a cell-permeable, reversible and specific inhibitor of Rac GTPase, used for cancer treatment.
Talatisamine
Talatisamine, a aconitum alkaloid, is specific K+ channel blocker. Talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons[1]. Talatisamine, a aconitum alkaloid, is specific K+ channel blocker. Talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons[1].
7beta-Hydroxy-14alpha-methyl-15-nor-pimar-13(16)c-en-17,19-disaeure-17-(2-methylamino-aethylester)-19-methylester|7beta-hydroxy-14alpha-methyl-15-nor-pimar-13(16)c-ene-17,19-dioic acid-17-(2-methylamino-ethyl ester)-19-methyl ester|Norcassamidin
7beta-Hydroxy-14alpha-methyl-15-nor-pimar-13(16)c-en-17,19-disaeure-17-[(2-hydroxy-aethyl)-methyl-amid]-19-methylester|7beta-hydroxy-14alpha-methyl-15-nor-pimar-13(16)c-ene-17,19-dioic acid-17-[(2-hydroxy-ethyl)-methyl-amide]-19-methyl ester|Norcassamidid
(6Z)-(1S,3R)-9,14,19,19,19-pentadeuterio-9,10-seco-5(10),6,8-cholestatriene-1,3,25-triol
U-46619 Glycine methyl ester
NSC 23766
NSC 23766 is a cell-permeable, reversible and specific inhibitor of Rac GTPase, used for cancer treatment.
CAR 18:3
C25H43NO4 (421.31919180000006)
(3a,5b,7a,12a)-3-Amino-7,12-dihydroxycholan-24-oic acid methyl ester
C25H43NO4 (421.31919180000006)
(3S,4R)-4-BENZYL-3-(3-METHYLPENTANOYL)-OXAZOLIDIN-2-ONE
N,N-bis[2-(octylamino)ethyl]-glycine hydrochloride
dimethyl hexadecyl ammoium butayl sulfate
C22H47NO4S (421.32256220000005)
Octyl 3-Amino-3-Deoxy-2-O-(2,6-Dideoxy-Alpha-L-Lyxo-Hexopyranosyl)-Beta-D-Galactopyranoside
(5Z,9Z,12Z)-Octadeca-5,9,12-trienoylcarnitine
C25H43NO4 (421.31919180000006)
(9Z,11E,13Z)-Octadeca-9,11,13-trienoylcarnitine
C25H43NO4 (421.31919180000006)
(8E,10E,12Z)-Octadeca-8,10,12-trienoylcarnitine
C25H43NO4 (421.31919180000006)
(8R,9S)-9-[[cyclopentylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C22H39N5O3 (421.30527440000003)
(8S,9S)-9-[[cyclopentylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C22H39N5O3 (421.30527440000003)
(8R,9S)-9-[[cyclopentylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C22H39N5O3 (421.30527440000003)
(8S,9R)-9-[[cyclopentylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C22H39N5O3 (421.30527440000003)
[(8R,9S,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
(8S,9R)-9-[[cyclopentylmethyl(methyl)amino]methyl]-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C22H39N5O3 (421.30527440000003)
(8R,9S)-9-[[cyclopentylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C22H39N5O3 (421.30527440000003)
(8S,9S)-9-[[cyclopentylmethyl(methyl)amino]methyl]-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C22H39N5O3 (421.30527440000003)
[(8R,9R,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9R,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9S,10S)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8S,9R,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
[(8R,9S,10R)-6-(4-oxanylmethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]-gamma-aminobutyric acid
An N-acyl-gamma-aminobutyric acid resulting from the formal condensation of the amino group of gamma-aminobutyric acid with the carboxy group of (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoic acid.
N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]-gamma-aminobutanoic acid
An N-acyl-amino acid resulting from the formal condensation of the amino group of gamma-aminobutyric acid with the carboxy group of (12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoic acid.
(9Z,12Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]octadeca-9,12-dienamide
N-[(4E,8E,12E)-1,3-dihydroxynonadeca-4,8,12-trien-2-yl]heptanamide
N-[(4E,8E,12E)-1,3-dihydroxyicosa-4,8,12-trien-2-yl]hexanamide
N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]nonanamide
(9Z,12Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]heptadeca-9,12-dienamide
N-[(4E,8E,12E)-1,3-dihydroxytricosa-4,8,12-trien-2-yl]propanamide
N-[(4E,8E,12E)-1,3-dihydroxytetracosa-4,8,12-trien-2-yl]acetamide
N-[(4E,8E,12E)-1,3-dihydroxyhenicosa-4,8,12-trien-2-yl]pentanamide
N-[(4E,8E,12E)-1,3-dihydroxyoctadeca-4,8,12-trien-2-yl]octanamide
(9Z,12Z,15Z)-N-(1,3-dihydroxyoctan-2-yl)octadeca-9,12,15-trienamide
N-[(4E,8E,12E)-1,3-dihydroxydocosa-4,8,12-trien-2-yl]butanamide
(Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]tridec-9-enamide
N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]decanamide
(Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]tetradec-9-enamide
N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]undecanamide
(9Z,12Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]hexadeca-9,12-dienamide
(7Z,10Z,13Z)-N-(1,3-dihydroxydecan-2-yl)hexadeca-7,10,13-trienamide
3-Hydroxy-2-(undecanoylamino)decane-1-sulfonic acid
C21H43NO5S (421.2861788000001)
2-(Decanoylamino)-3-hydroxyundecane-1-sulfonic acid
C21H43NO5S (421.2861788000001)
N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]dodecanamide
(Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]dodec-5-enamide
(4S)-4-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyl]oxy-4-(trimethylazaniumyl)butanoate
C25H43NO4 (421.31919180000006)
(4S)-4-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]-4-(trimethylazaniumyl)butanoate
C25H43NO4 (421.31919180000006)
SPHP(22:0)
C22H48NO4P (421.33207780000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
16-(4-hydroxy-4-methylpent-2-en-1-yl)-1,16,20-trimethyl-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-ol
5-(5-hydroxyoctyl)-2-methyl-decahydroquinolin-3-yl oct-2-enoate
methyl (1s,4ar,4bs,7e,8r,8ar,9s,10ar)-9-hydroxy-7-{[(2-hydroxyethyl)(methyl)carbamoyl]methylidene}-1,4a,8-trimethyl-decahydro-2h-phenanthrene-1-carboxylate
methyl (1s,4ar,4bs,7e,8r,8ar,9r,10as)-9-hydroxy-1,4a,8-trimethyl-7-{2-[2-(methylamino)ethoxy]-2-oxoethylidene}-decahydro-2h-phenanthrene-1-carboxylate
methyl (1s,4ar,4bs,8r,8ar,9r,10as)-9-hydroxy-1,4a,8-trimethyl-7-{2-[2-(methylamino)ethoxy]-2-oxoethylidene}-decahydro-2h-phenanthrene-1-carboxylate
(6s,8s,13s)-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol
(4r,4as,7r,8s,8as)-7-hydroxy-8-(1h-indol-3-ylmethyl)-4,4a,7-trimethyl-8a-(4-methylpent-3-en-1-yl)-hexahydronaphthalen-1-one
methyl 9-hydroxy-7-{[(2-hydroxyethyl)(methyl)carbamoyl]methylidene}-1,4a,8-trimethyl-decahydro-2h-phenanthrene-1-carboxylate
(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18r)-11-ethyl-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,18-diol
(2r,3r,4as,5s,8ar)-5-[(5s)-5-hydroxyoctyl]-2-methyl-decahydroquinolin-3-yl (2e)-oct-2-enoate
methyl (1s,4ar,4bs,7e,8r,8ar,9s,10ar)-9-hydroxy-1,4a,8-trimethyl-7-{2-[2-(methylamino)ethoxy]-2-oxoethylidene}-decahydro-2h-phenanthrene-1-carboxylate
(1s,2r,3r,4r,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol
(2r,3r,4as,5s,8ar)-5-[(5r)-5-hydroxyoctyl]-2-methyl-decahydroquinolin-3-yl (2e)-oct-2-enoate
(1s,4r,4as,5r,7r,7as,8s,9r,11as)-8-(1h-indol-3-yl)-4,4a,7-trimethyl-9-(prop-1-en-2-yl)-dodecahydrocyclohexa[e]naphthalene-1,5-diol
(1r,4as,4br,7r,8s,8ar,10as)-8-[(6-hydroxy-1h-indol-3-yl)methyl]-1,4b,7,8,10a-pentamethyl-decahydrophenanthren-2-one
(1r,2r,3r,4r,5s,6s,8r,9s,10s,13s,16r,17s,18s)-11-ethyl-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,18-diol
2-[7-(1h-indol-3-ylmethyl)-6a,10b-dimethyl-8-methylidene-decahydronaphtho[2,1-b]pyran-3-yl]propan-2-ol
8-(1h-indol-3-yl)-9-isopropyl-4,4a,7-trimethyl-1h,2h,3h,4h,5h,6h,7h,7ah,10h,11h-cyclohexa[e]naphthalene-1,5-diol
(2r,3r,4s,5s,6s,8s,13s,16s,17r)-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol
3-(hexan-2-yl)-7-methoxy-10,12-dimethyl-3h,4h,5h,6h,7h,8h,9h,10h,15h,16h,17h,17ah-pyrrolo[2,1-c]1-oxa-4-azacyclopentadecane-1,13-dione
C25H43NO4 (421.31919180000006)
7-hydroxy-8-(1h-indol-3-ylmethyl)-4,4a,7-trimethyl-8a-(4-methylpent-3-en-1-yl)-hexahydronaphthalen-1-one
(1r,4s,5r,8s,9s,10r,13s)-8-hydroxy-4,5-dimethyl-9-(4-methylpent-3-en-1-yl)-14-azapentacyclo[11.7.1.0¹,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-15,17,19-trien-12-one
8-(1h-indol-3-yl)-4,4a,7-trimethyl-9-(prop-1-en-2-yl)-dodecahydrocyclohexa[e]naphthalene-1,5-diol
2-[(3s,4as,6ar,7r,10ar,10bs)-7-(1h-indol-3-ylmethyl)-6a,10b-dimethyl-8-methylidene-decahydronaphtho[2,1-b]pyran-3-yl]propan-2-ol
(2r,3s,4ar,5r,8as)-5-(5-hydroxyoctyl)-2-methyl-decahydroquinolin-3-yl (2e)-oct-2-enoate
methyl 9-hydroxy-1,4a,8-trimethyl-7-{2-[2-(methylamino)ethoxy]-2-oxoethylidene}-decahydro-2h-phenanthrene-1-carboxylate
(1s,4r,4as,5r,7r,7as,8r,11ar)-8-(1h-indol-3-yl)-9-isopropyl-4,4a,7-trimethyl-1h,2h,3h,4h,5h,6h,7h,7ah,8h,11h-cyclohexa[e]naphthalene-1,5-diol
8-(1h-indol-3-yl)-9-isopropyl-4,4a,7-trimethyl-1h,2h,3h,4h,5h,6h,7h,7ah,8h,11h-cyclohexa[e]naphthalene-1,5-diol
(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18r)-11-ethyl-6,16,18-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol
(1r,4s,4ar,5r,7s,7ar,8r,9s,11ar)-8-(1h-indol-3-yl)-4,4a,7-trimethyl-9-(prop-1-en-2-yl)-dodecahydrocyclohexa[e]naphthalene-1,5-diol
(1s,12s,15r,16s,17s,20s)-16-[(2e)-4-hydroxy-4-methylpent-2-en-1-yl]-1,16,20-trimethyl-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-ol
(1s,2r,3r,4s,5s,6s,8s,13s,16s,17r)-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol
(1s,2r,3r,4s,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8-diol
n-[(2s)-1-hydroxy-13-(4-methyl-5-pentylfuran-2-yl)-3-oxotridecan-2-yl]ethanimidic acid
C25H43NO4 (421.31919180000006)
(1r,4ar,4br,7r,8s,8as,10ar)-8-[(6-hydroxy-1h-indol-3-yl)methyl]-1,4b,7,8,10a-pentamethyl-decahydrophenanthren-2-one
(3s,17as)-3-[(2r)-hexan-2-yl]-7-methoxy-10,12-dimethyl-3h,4h,5h,6h,7h,8h,9h,10h,15h,16h,17h,17ah-pyrrolo[2,1-c]1-oxa-4-azacyclopentadecane-1,13-dione
C25H43NO4 (421.31919180000006)